Literature DB >> 3814461

Quantitative and qualitative binding characteristics of disopyramide in serum from patients with decreased renal and hepatic function.

L E Pedersen, J Bonde, N A Graudal, N V Backer, J E Hansen, J P Kampmann.   

Abstract

Protein binding of disopyramide, binding capacities, affinity constants and serum concentrations of alpha 1-acid glycoprotein (AAG) were studied in five groups of patients. A: young healthy volunteers (n = 8); B: elderly patients with minor symptoms of ischaemic heart disease (n = 9); C: patients with cirrhosis of the liver and normal values of coagulation factors (II, VII and X), albumin and immunoglobulin G (n = 8); D: patients with cirrhosis and at least two abnormal of the previously mentioned values (n = 9) and E: eleven patients with severely impaired renal function. Subfractions of AAG (Fr1, Fr2 and Fr3) were determined by affinoimmunoelectrophoresis. AAG concentration was significantly (P less than 0.005) elevated in group E patients and decreased (P less than 0.025) in group D patients. Fr2 is probably associated with the high affinity, first binding site of disopyramide to AAG. Earlier observations of a reduced qualitative binding of disopyramide in patients with cirrhosis can be explained by a significant decrease in Fr2 (P less than 0.001) in group D patients. The protein binding of disopyramide in patients with uraemia was significantly increased due to a significant (P less than 0.005) increase in AAG concentration in spite of a smaller (P less than 0.025) affinity constant. Suggestions for therapeutic drug monitoring based on total serum concentrations are given.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3814461      PMCID: PMC1386138          DOI: 10.1111/j.1365-2125.1987.tb03007.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

1.  A graphic method for the determination and presentation of binding parameters in a complex system.

Authors:  H E Rosenthal
Journal:  Anal Biochem       Date:  1967-09       Impact factor: 3.365

2.  The effects of urine pH and plasma protein binding on the renal clearance of disopyramide.

Authors:  J L Cunningham; D D Shen; I Shudo; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1977 Sep-Oct       Impact factor: 6.447

3.  [Quantitative variations of serum glycoproteins in pathological processes; determination of aicd alpha-l-glycoprotein, Gc and alpha-2-macroglobulin using radial immunodiffusion].

Authors:  H Cleve; G Strohmeyer
Journal:  Klin Wochenschr       Date:  1967-10-15

4.  Decreased alpha 1-acid glycoprotein in liver cirrhosis: consequences for drug protein binding.

Authors:  J Barre; G Houin; J Rosenbaum; R Zini; D Dhumeaux; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

5.  The variation in twenty-one serum proteins before and after renal transplantation. I. General pattern.

Authors:  B Weeke; E Weeke; G Bendixen
Journal:  Acta Med Scand       Date:  1971 Jan-Feb

6.  Relationship between alpha 1-acid glycoprotein and plasma binding of disopyramide and mono-N-dealkyldisopyramide.

Authors:  J E Bredesen; P Kierulf
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

7.  The effects of age and smoking on the plasma protein binding of lignocaine and diazepam.

Authors:  D Davis; S H Grossman; B B Kitchell; D G Shand; P A Routledge
Journal:  Br J Clin Pharmacol       Date:  1985-02       Impact factor: 4.335

8.  The serum protein profile in chronic hepatitis, cirrhosis and liver cancer.

Authors:  S Hiramatsu; J Kojima; T T Okada; S Inai; K Ohmori
Journal:  Acta Hepatogastroenterol (Stuttg)       Date:  1976-06

9.  Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients.

Authors:  D B Haughey; C J Kraft; G R Matzke; W F Keane; C E Halstenson
Journal:  Am J Nephrol       Date:  1985       Impact factor: 3.754

10.  The influence of age and smoking on the elimination of disopyramide.

Authors:  J Bonde; L E Pedersen; S Bødtker; H R Angelo; T L Svendsen; J P Kampmann
Journal:  Br J Clin Pharmacol       Date:  1985-11       Impact factor: 4.335

View more
  11 in total

Review 1.  Methods of determining plasma and tissue binding of drugs. Pharmacokinetic consequences.

Authors:  G M Pacifici; A Viani
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

Review 2.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics in patients with liver disease.

Authors:  A J McLean; D J Morgan
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

4.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria.

Authors:  K Silamut; P Molunto; M Ho; T M Davis; N J White
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

5.  Variation in serum binding of tertatolol mediated by disease-induced modification of alpha-acid glycoprotein concentration.

Authors:  S Urien; D Morin; A Renouard; I Rocher; J P Tillement
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

6.  Differences in the serum binding determinants of isradipine and darodipine--consequences for serum protein binding in various diseases.

Authors:  J L Pinquier; S Urien; P Chaumet-Riffaud; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

7.  Influence of continuous ambulatory peritoneal dialysis on serum alpha 1-acid glycoprotein concentration and drug binding.

Authors:  F M Belpaire; E J Van de Velde; N H Fraeyman; M G Bogaert; N Lameire
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

8.  Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.

Authors:  R Zini; D Morin; C Salvadori; J P Tillement
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

9.  Does alpha 1-acid glycoprotein reduce the unbound metabolic clearance of disopyramide in patients with renal impairment?

Authors:  J Braun; F Sörgel; W P Gluth; S Oie
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 10.  Disopyramide. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiac arrhythmias.

Authors:  R N Brogden; P A Todd
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.